4SC 205

Drug Profile

4SC 205

Alternative Names: 4SC-205

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nycomed
  • Developer 4SC
  • Class Antineoplastics; Small molecules
  • Mechanism of Action KIF11 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Lymphoma; Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Lymphoma in Germany (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in Germany (PO, Tablet)
  • 08 Jun 2016 4SC 205 is available for licensing in countries, except China, Hong Kong, Taiwan and Macao, as of 31 May 2016. http://www.4sc.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top